Rising Sarcoma Surgery Rates in Germany May Be a Data Artifact, Researchers Warn

A rare and formidable cancer has become the center of an unusually pointed scientific dispute. Retroperitoneal sarcoma, a tumor that grows in the deep space behind the abdominal organs, is so uncommon that most surgeons will encounter only a handful of cases in an entire career. Because no single hospital can accumulate meaningful experience with the disease, researchers increasingly turn to national cancer registries to answer questions that individual institutions cannot. A recent nationwide analysis from the German Cancer Registry Group, led by Beck and colleagues and published in the Journal of Cancer Research and Clinical Oncology, did exactly that: it examined treatment patterns for retroperitoneal sarcoma across Germany between 2000 and 2022, drawing on more than two decades of registry records to describe how surgical practice has evolved. The study reported a striking finding, namely that multivisceral resection, the removal of the sarcoma together with adjacent organs such as the kidney, spleen, pancreas, or colon, rose from roughly twelve percent of cases in 2001 to approximately fifty percent in recent years. That trajectory, the authors argued, reflects a genuine national shift toward guideline-concordant surgery for liposarcoma, the most common histological subtype of the disease.

Now a team of researchers from Meenakshi Medical College Hospital and Research Institute in Tamil Nadu, India, has published a formal commentary in the same journal challenging that interpretation. In a Matters Arising contribution, R. Saravanan, Paramanantham Madhavan, R. Sivayogana, and K. Anusha do not dispute the value of the underlying registry analysis, which they describe as an important framework for evaluating rare cancers using population-level data. Instead, they raise two methodological concerns that, if correct, could substantially alter how the German findings should be read. The first concerns whether the apparent rise in multivisceral resection reflects a real change in surgical practice or simply an improvement in how operations were documented and coded over time. The second concerns the handling of missing data on tumor grade and metastatic status, variables that were absent in a large fraction of cases yet still used to stratify survival analyses. Both concerns strike at the heart of a growing movement in oncology: the use of registry data to draw clinical conclusions about diseases too rare for randomized trials.

The argument about coding is technically subtle but conceptually compelling. The German analysis of organ resections relied on a subset of only 1,318 patients with codeable resection procedures, a considerably smaller group than the full surgical cohort, and it depended entirely on whether the Operationen- und Prozedurenschlüssel, the German procedure coding system, captured a code for every organ removed during each operation. The commentary points out that the original paper itself acknowledged a parallel phenomenon: the rise in annual case numbers over the same period was attributed to improving case ascertainment and documentation completeness following the 2014 legal framework for cancer registration, not to a true increase in disease incidence. If overall case documentation improved across two decades, the Indian authors argue, it is plausible and untested that procedure-level documentation improved as well. Under that scenario, earlier multivisceral resections may have been underdocumented, with only the single most prominent procedure code recorded, while later cases benefited from more complete coding that captured every organ removed in the same operation. Part or all of the observed temporal trend would then reflect better paperwork rather than bolder surgery.

The distinction is far more than methodological tidiness. If the trend is substantially a documentation artifact, the commentary notes, then the implicit message to clinicians and registry stewards, that German surgical practice has progressively converged on international multivisceral resection guidelines for liposarcoma, would be overstated. The more accurate takeaway would concern the maturation of registry coding rather than the maturation of surgical decision-making. The authors propose a concrete diagnostic test: reporting the proportion of surgical cases with at least one codeable resection procedure by diagnosis year, alongside the existing organ-count trend, would allow readers to judge whether the apparent rise in multivisceral resection tracks improving procedure documentation or represents an independent change in clinical practice. If the two curves move together, the documentation explanation gains weight; if they diverge, the practice-change interpretation becomes more credible. Such a check costs nothing beyond additional analysis of data already in hand, which is precisely why the commentary frames its absence as a missed opportunity.

The second major concern involves missing data in the survival analyses. According to the commentary, grading information was missing in twenty-four percent of cases, and distant metastasis status was missing in fifty-five percent, yet both variables were used to stratify the survival analyses and the primary treatment description without any sensitivity analysis addressing whether the missingness was informative. This matters because of a well-known statistical hazard: complete-case analysis, in which patients lacking a given variable are simply excluded, produces unbiased results only if the missing data occur randomly. If, as the original paper’s own discussion suggests, earlier-era cases suffered from less complete documentation, then those cases may be disproportionately represented among patients with missing grading or staging information. The Kaplan-Meier survival curves and treatment-pattern tables restricted to complete cases would then systematically overrepresent more recent, better-documented tumors, which may differ from the excluded cases in surgical approach, tumor biology ascertainment, or case mix. The resulting curves could paint a rosier or otherwise distorted picture of outcomes across the full registry cohort.

The commentary applies this concern specifically to the Kaplan-Meier estimates stratified by grade, which were calculated only among the roughly three-quarters of cases with recorded grading. No comparison of baseline characteristics between graded and ungraded cases was provided to establish that the two groups were otherwise similar. The authors suggest a remedy that mirrors their proposal on procedure coding: reporting whether missingness in grading and metastasis status varies systematically by diagnosis year, and providing a basic comparison of age, sex, and histology distribution between complete and incomplete cases. Such comparisons would allow readers to judge whether the survival and treatment-pattern findings generalize to the full registry cohort or are specific to the more thoroughly documented subset. The commentary also notes an internal inconsistency in the original paper’s logic: the study elsewhere treats improving documentation completeness as a plausible explanation for other temporal patterns in the dataset, yet does not extend that same reasoning to the grading and staging variables underlying the survival analysis.

What makes this exchange notable is its constructive tone and its broader relevance. The Indian authors explicitly state that neither concern displaces the substantial contribution of the German study, which established a reproducible, histology- and location-specific framework for extracting a rare tumor cohort from national registry data. They call that framework a genuinely useful methodological template for future rare-cancer registry research well beyond retroperitoneal sarcoma. The stakes they identify are correspondingly high: distinguishing genuine practice change from improved documentation completeness, and characterizing whether missing data correlate with diagnosis era, would allow clinicians and health-policy readers to rely on reported trends as evidence of evolving surgical practice with greater confidence, rather than treating documentation artifacts as clinical signals. In an era when health systems increasingly mine administrative and registry data to guide cancer care, the commentary is a reminder that the quality of the data pipeline can be as consequential as the quality of the medicine it records.

The technical issues at play are familiar to epidemiologists but deserve wider understanding. Procedure coding systems like the German OPS are designed for billing and administration, not research, and their granularity depends on local coding habits, staffing, and evolving regulations. Studies of complex surgical specimens in other fields have documented substantial variability in how thoroughly multi-organ procedures are captured in coded records, and the commentary cites work on procedural terminology optimization in genitourinary surgery as an illustration. Similarly, the problem of informative missingness in registry-based survival analysis has prompted a growing literature on imputation techniques for Kaplan-Meier estimation, which the commentary references. Neither problem is unique to the German study; both are endemic to registry research. The commentary’s contribution is to show how these general hazards map onto the specific claims of a high-profile national analysis, and to propose analyses that would resolve the ambiguity without requiring new data collection.

For patients with retroperitoneal sarcoma, the practical implications are indirect but real. Multivisceral resection is the single most important determinant of long-term survival in this disease, and international guidelines recommend aggressive compartmental surgery for liposarcoma whenever feasible. If German practice has genuinely converged on those guidelines over two decades, that is encouraging news for the roughly one in a hundred thousand people diagnosed each year. If instead the trend partly reflects coding maturation, the appropriate response is not complacency about surgery but investment in registry quality, so that future analyses can distinguish the two. The commentary, published open access in October 2026, ultimately asks for methodological consistency: the same skepticism about documentation quality that the original authors applied to case counts should be applied to procedure codes, tumor grades, and staging data. Whether the German group responds with the requested sensitivity analyses will determine how confidently the oncology community can cite this study as evidence that surgical practice, and not merely surgical record-keeping, has changed.

Subject of Research: Methodological evaluation of German cancer registry data on retroperitoneal sarcoma treatment trends

Article Title: Comment on “Treatment of retroperitoneal sarcoma in Germany between 2000 and 2022: a retrospective analysis from the German Cancer Registry Group”

Article References: Comment on “Treatment of retroperitoneal sarcoma in Germany between 2000 and 2022: a retrospective analysis from the German Cancer Registry Group”. (n.d.). https://doi.org/10.1007/s00432-026-06591-w

Image Credits: AI Generated

DOI: 10.1007/s00432-026-06591-w

Keywords: retroperitoneal sarcoma, cancer registry, multivisceral resection, registry completeness, missing data, survival analysis, surgical oncology, liposarcoma, rare cancers, clinical epidemiology, procedure coding, Germany